Biotech (688177.SH): BAT2206 (usinumab) injection approved for marketing by the US FDA

Zhitong Finance App News, Biotech (688177.SH) issued an announcement. The company recently received a notice from the US Food and Drug Administration (hereinafter referred to as “US FDA”) regarding approval for the marketing of BAT2206 (usinumab) injection (US trade name: STARJEMZA).

Indications for the drug: Adult indications: moderate to severe plaque psoriasis (PsO), active psoriatic arthritis (pSA), moderate to severe active Crohn's disease (CD), moderate to severe active ulcerative colitis (UC); Pediatric indications: moderate to severe plaque psoriasis (PsO), active psoriatic arthritis (PsA).

BAT2206 (usinumab) injection (US trade name: STARJEMZA), as another product approved by Biotech's US FDA, will further expand the company's international market, enhance the international influence of the company's products, and is expected to have a positive impact on the company's long-term business performance. As of the announcement disclosure date, a number of usinumab injections around the world have been approved for marketing by the US FDA. The competitors that have already been marketed and other potential competitors may have a pioneer advantage, and BAT2206 (usinumab) injections may face fierce market competition in the future.